



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/668,792	09/23/2003	Bernard E. Cabana	4354-110	4322
23448	7550	09/21/2011	EXAMINER	
Hultquist IP			SPIVACK, PHYLLIS G	
P.O. Box 14329			ART UNIT	
RESEARCH TRIANGLE PARK, NC 27709			PAPER NUMBER	
			1629	
			MAIL DATE	
			DELIVERY MODE	
			09/21/2011	
			PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Examiner-Initiated Interview Summary	Application No. 10/668,792	Applicant(s) CABANA ET AL.	
	Examiner PHYLLIS SPIVACK	Art Unit 1629	

All participants (applicant, applicant's representative, PTO personnel):

- (1) Phyllis Spivack. (3) ____.
- (2) David Bradin. (4) ____.

Date of Interview: 16 September 2011.

Type: ☒ Telephonic ☐ Video Conference
☐ Personal [copy given to: ☐ applicant ☐ applicant's representative]

Exhibit shown or demonstration conducted: ☐ Yes ☐ No.
If Yes, brief description: ____.

Issues Discussed ☐ 101 ☐ 112 ☐ 102 ☐ 103 ☒ Others
(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)

Claim(s) discussed: 1, 2, 4, 5, 52 and 62.

Identification of prior art discussed: ____.

Substance of Interview

(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)

In response to the Amendment filed August 18, 2011, the Examiner contacted Mr. Bradin concerning a potential new matter issue. The recitations of ranges, "an amount between 0.1 and 0.25 mg" in claim 1 and "an amount between 0.1 and 0.5 mg" in claim 2, do not find clear support in the specification. A follow-up discussion will take place on September 19 or 20 to determine whether or not the discrete amounts of 0.1 mg and 0.5 mg find support in the specification.

Applicant recording instructions: It is not necessary for applicant to provide a separate record of the substance of interview.

Examiner recording instructions: Examiners must summarize the substance of any interview of record. A complete and proper recollection of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recollection including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

☐ Attachment

/Phyllis G. Spivack/
Primary Examiner, Art Unit 1629